Drug resistance in anti-TNF therapy of psoriatic arthritis

Dominika Ligia Wcisło-Dziadecka; Beniamin Grabarek; Ligia Brzezińska-Wcisło; Urszula Mazurek

doi:10.5114/dr.2018.79175

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

5/2018
vol. 105

Send email

Copy url:

abstract:

Case report

Drug resistance in anti-TNF therapy of psoriatic arthritis

Dominika Ligia Wcisło-Dziadecka

,

Beniamin Grabarek

,

Ligia Brzezińska-Wcisło

,

Urszula Mazurek

Dermatol Rev/Przegl Dermatol 2018, 105, 625–631

DOI: https://doi.org/10.5114/dr.2018.79175

Online publish date: 2018/11/08

View full text Get citation

PlumX metrics:

Introduction
Despite of the molecular targeting anti-TNF therapy, drug resistance may be observed. A method of avoiding this phenomenon, changing treatment early and increasing its effectiveness, the new molecular markers may be used.

Objective
To present clinical (PASI, BSA, DAS28, DLQI) and molecular (TNF-α, TNFR1, TNFR2) parameters of loss of efficacy to etanercept in a patient with psoriatic arthritis.

Case report
Patient aged 64, initially treated with etanercept then adalimumab because of psoriatic arthritis. During the observation, the loss of response to the anti-TNF drug was observed. During subsequent visits, whole blood was collected from the patient for molecular analysis based on the RTqPCR.

Conclusions
Molecular markers such as TNF-α, TNFR1, TNFR2 seem to be useful for early detection of drug resistance and fit into the model of personalised medicine.

keywords:

Drug resistance in anti-TNF therapy of psoriatic arthritis

Dominika Ligia Wcisło-Dziadecka , Beniamin Grabarek , Ligia Brzezińska-Wcisło , Urszula Mazurek

anti-TNF therapy, psoriasis, resistance in therapy, molecular marker

Dominika Ligia Wcisło-Dziadecka

,

Beniamin Grabarek

,

Ligia Brzezińska-Wcisło

,

Urszula Mazurek